Zepbound Future Formulations & Pipeline: What Women Need to Know

How Zepbound Works: The Dual-Receptor Mechanism Women Should Understand

Zepbound is not a simple GLP-1 drug. It acts simultaneously on two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. This dual action produces appetite suppression, slower gastric emptying, and improved insulin sensitivity through overlapping but distinct pathways.

Why does this matter for women specifically? Because GIP receptor expression and downstream insulin sensitivity are influenced by estrogen. Research in rodent models has shown that estrogen potentiates GIP-stimulated insulin secretion, which means tirzepatide's GIP component may behave differently across the menstrual cycle and in postmenopausal women with lower circulating estrogen. Direct human pharmacokinetic data stratified by hormonal status are limited, and this is an acknowledged evidence gap that WomanRx flags clearly: the SURMOUNT-1 trial did not publish a primary sex-hormone-stratified subgroup analysis.

GIP vs. GLP-1: What Each Receptor Does

GLP-1 receptor agonism reduces appetite and slows gastric emptying. It also reduces glucagon secretion. These effects are well characterized in semaglutide data. The GIP component adds complementary appetite suppression and may improve lipid handling in adipose tissue, which is why tirzepatide's weight-loss magnitude exceeds semaglutide's in head-to-head data.

Why the Dual Mechanism May Be Especially Relevant in PCOS

Women with polycystic ovary syndrome carry a disproportionate burden of insulin resistance. Approximately 50-70% of women with PCOS have some degree of insulin resistance, regardless of BMI. Tirzepatide's dual receptor action targets both glucose disposal and appetite regulation, making it a mechanistically attractive option for this population. Dedicated PCOS trials are not yet complete, but mechanistic rationale is strong.

The SURMOUNT Trial Program: Where the Evidence Stands Now

SURMOUNT-1: The Foundational Trial

The SURMOUNT-1 trial enrolled 2,539 adults with a BMI of at least 30, or at least 27 with at least one weight-related comorbidity, and without diabetes. Participants were randomized to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks. The 15 mg dose produced a mean weight loss of 20.9% of body weight versus 3.1% with placebo. Roughly 37% of participants on 15 mg achieved at least 25% body-weight loss.

Women made up approximately 67% of the SURMOUNT-1 population. The trial did not publish prospectively planned sex-specific efficacy analyses in the primary paper, which is a gap. Post-hoc analyses circulating in conference abstracts suggest women achieved numerically similar or slightly greater percentage weight loss than men, consistent with GLP-1 trial patterns, but these data have not been peer-reviewed in final form.

SURMOUNT-2, 3, and 4

SURMOUNT-2 enrolled adults with type 2 diabetes and showed 15.7% weight loss at 72 weeks on 15 mg tirzepatide. SURMOUNT-3 tested a lead-in intensive lifestyle intervention before randomization. SURMOUNT-4 examined weight regain after drug discontinuation and confirmed that stopping tirzepatide led to regain of roughly two-thirds of lost weight within one year, reinforcing that this is a chronic therapy for a chronic condition.

SURMOUNT-OSA

The SURMOUNT-OSA trial, published in 2024, showed tirzepatide reduced the apnea-hypopnea index by up to 62.8% in adults with obesity-related obstructive sleep apnea. This is directly relevant to perimenopausal and postmenopausal women, who experience a steep rise in sleep apnea prevalence after menopause due to hormonal changes affecting upper airway muscle tone and fat distribution. The FDA approved this new indication for Zepbound in June 2024, making it the first drug approved specifically for obesity-related sleep apnea.

The Pipeline: What Is Coming for Zepbound and Tirzepatide

This section organizes Eli Lilly's tirzepatide pipeline into three tiers relevant to women: new delivery forms, new indications, and next-generation molecule combinations. Competitor coverage lumps pipeline items together without differentiating which stages have human data versus preclinical signals. This framework helps you weigh the strength of each development.

Tier 1: New Delivery Forms with Active Human Data

Oral Tirzepatide Tablet

Oral GLP-1 delivery has been the field's most sought-after goal since semaglutide's oral form (Rybelsus) launched for type 2 diabetes in 2019. Eli Lilly is developing an oral tirzepatide formulation using a permeation enhancer technology. Phase 1 data presented at the American Diabetes Association 2024 scientific sessions showed dose-dependent plasma exposure in healthy volunteers.

Phase 2 dose-finding in adults with obesity is ongoing as of early 2025, with results expected in 2025 or 2026. If bioavailability challenges are solved, oral tirzepatide would remove the barrier of weekly injection. For women with needle anxiety, those who travel frequently for work, and postpartum women managing a newborn, an oral option would change real-world adherence substantially.

One pharmacokinetic note: oral GLP-1 drugs are known to have high within-patient variability in absorption, partly because food intake timing and gastric emptying rate affect bioavailability. Women have slower average gastric emptying than men at baseline, which may influence both peak exposure and tolerability of an oral formulation. This sex difference in gastric physiology has not been formally studied for oral tirzepatide and represents an evidence gap.

Next-Generation Autoinjector

Eli Lilly has filed patents and disclosed development of a prefilled autoinjector for tirzepatide designed to replace the current multi-step injection device. This autoinjector would use a shorter needle, a push-button mechanism, and a smaller injection volume. No trial-level clinical data are published yet, but device studies are standard pre-commercialization work. An improved autoinjector matters for women with injection-site fatigue, those injecting through abdominal adipose tissue that changes with hormonal cycles, and postpartum women whose abdominal skin is more sensitive.

Tier 2: New Indications with Phase 2 or Phase 3 Data

Heart Failure with Preserved Ejection Fraction (HFpEF)

The SUMMIT trial, published in The Lancet in 2024, showed tirzepatide improved exercise capacity and reduced heart failure symptoms in adults with obesity-related HFpEF. Women represent the majority of HFpEF patients, partly because menopause-associated changes in ventricular compliance and adiposity distribution drive this phenotype. This indication is under FDA review.

Non-Alcoholic Steatohepatitis (MASH/NASH)

Tirzepatide is in Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Women with PCOS have elevated MASH risk, and postmenopausal women experience accelerated hepatic fat accumulation due to the loss of estrogen's protective effects on hepatic lipid metabolism. Phase 2 data published in The New England Journal of Medicine in 2024 showed tirzepatide achieved MASH resolution without worsening fibrosis in 62.4% of participants on the 10 mg dose versus 22.5% on placebo.

Chronic Kidney Disease

A Phase 3 trial in obesity-related chronic kidney disease is underway. Women with PCOS-associated metabolic disease and women with hypertension entering menopause carry elevated CKD risk. Tirzepatide's renal effects are being formally studied, though sex-stratified interim results are not yet available.

Type 1 Diabetes (Adjunct)

Small investigator-initiated studies have examined tirzepatide as an adjunct in type 1 diabetes to reduce total daily insulin dose and support weight management. Women with type 1 diabetes face specific challenges including menstrual-cycle-driven glycemic variability and weight gain from intensive insulin regimens. No Phase 3 data are published yet.

Tier 3: Preclinical and Early Signals

Retatrutide: Triple GIP/GLP-1/Glucagon Agonist

Retatrutide is a separate Lilly molecule. It adds glucagon receptor agonism to the GIP and GLP-1 mechanism. Phase 2 data published in the New England Journal of Medicine in 2023 showed mean weight loss of up to 24.2% at 48 weeks on the highest dose (12 mg). This exceeds tirzepatide's 72-week result in a shorter timeframe, though the comparison is indirect and the populations differ. Glucagon agonism increases energy expenditure, which may help address the metabolic adaptation that typically blunts weight loss over time. Phase 3 trials are planned.

For women, glucagon's role in hepatic glucose output during luteal-phase hormonal shifts and its interaction with estrogen-regulated hepatic metabolism are theoretically relevant, but no sex-specific data from retatrutide trials are published.

Tirzepatide Plus Bimagrumab

Bimagrumab is an anti-ActRII antibody that promotes lean mass gain while reducing fat mass. Eli Lilly has disclosed interest in combination approaches that preserve or build muscle during GLP-1-driven weight loss. This is particularly important for women, because women lose proportionally more lean mass than fat mass during rapid weight loss compared with men, and perimenopausal and postmenopausal women are already at risk for sarcopenia. A combination that protects muscle while reducing fat mass would address one of the most clinically meaningful concerns about GLP-1 therapy in older women.

Pregnancy, Lactation, and Contraception: What You Must Know

Zepbound is contraindicated in pregnancy. The FDA label carries a warning based on animal reproductive toxicity data: in rat and rabbit studies, tirzepatide caused fetal harm at exposures below the maximum recommended human dose. No adequate human data on tirzepatide use in pregnant women exist.

Before You Conceive

Eli Lilly recommends discontinuing tirzepatide at least one month before a planned pregnancy, because the drug's half-life is approximately 5 days and meaningful plasma concentrations persist for approximately 4 weeks after the final dose. Women who are trying to conceive should stop tirzepatide and use effective contraception until confirmed cessation of the drug, then transition to preconception planning with their provider.

For women with PCOS who may become newly fertile after weight loss on tirzepatide (ovulation can resume as BMI decreases), unintended pregnancy is a real risk. ACOG advises that all women of reproductive age on teratogenic or pregnancy-risk medications receive counseling about contraception at every visit. Tirzepatide slows gastric emptying, which may reduce absorption of oral contraceptive pills during the first weeks of treatment. If you rely on oral contraceptives for pregnancy prevention while taking Zepbound, barrier backup for 4 weeks after starting tirzepatide or after each dose escalation is a reasonable precaution, though direct pharmacokinetic interaction studies for tirzepatide with oral contraceptives are not published.

Lactation

No human data on tirzepatide transfer into breast milk exist. Given the drug's molecular weight and peptide structure, transfer is likely low, but "likely low" is not "confirmed safe." The FDA label advises against use during breastfeeding. For postpartum women with obesity who are breastfeeding, the discussion about when to restart tirzepatide should weigh the clinical urgency of weight management against the duration of planned nursing, and should happen with an obesity medicine or maternal-fetal medicine specialist.

Fertility and PCOS

Weight loss of 5-10% of body weight is associated with resumption of ovulation in anovulatory women with PCOS. Tirzepatide's weight-loss magnitude far exceeds this threshold in most responders. Women with PCOS using tirzepatide for weight management should be counseled explicitly that fertility may return, sometimes rapidly, and that contraception planning is required if pregnancy is not desired.

Who This Is Right For, and Who Should Wait

Reproductive-Age Women (18-40)

Tirzepatide is appropriate for women with a BMI of at least 30, or at least 27 with a weight-related comorbidity such as PCOS, insulin resistance, hypertension, or dyslipidemia. The need for reliable contraception and a clear stop-before-conception plan must be part of the conversation before prescribing.

Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use tirzepatide or any GLP-1/GIP receptor agonist.

Trying to Conceive

Tirzepatide should be discontinued at least one month before attempting conception. Weight loss achieved before stopping the drug is beneficial for fertility, and the period after stopping can be used for preconception optimization including folate supplementation and metabolic labs.

Perimenopausal Women (40-55)

This is a group that stands to benefit considerably and that is often overlooked in GLP-1 trials. Perimenopause brings shifting estradiol levels, increasing central adiposity, insulin resistance, and a rise in cardiovascular risk. Tirzepatide addresses multiple aspects of this metabolic shift. Contraception remains relevant during perimenopause: ovulation continues intermittently until menopause is confirmed (12 consecutive months without a menstrual period), so pregnancy risk persists and the contraindication applies.

Postmenopausal Women

Postmenopausal women have confirmed cessation of ovulation, so the teratogenicity concern does not apply. The practical pipeline items most relevant to this group are the HFpEF indication, the MASH Phase 3 data, and the potential muscle-preserving combination therapies, all of which address conditions that concentrate in older women.

Women With a History of Eating Disorders

GLP-1 and dual GIP/GLP-1 drugs suppress appetite and alter food-reward signaling. For women with a history of restrictive eating disorders, this appetite suppression may create risk. No large prospective data exist specifically for this population. Clinical judgment and close monitoring are required.

Dosing, Escalation, and Female-Specific Tolerability Notes

Tirzepatide starts at 2.5 mg weekly for the first 4 weeks, escalates in 2.5 mg steps every 4 weeks to a maintenance dose of 5 mg, 10 mg, or 15 mg depending on tolerability and response. The FDA-approved label permits slower escalation if GI side effects limit uptitration.

Women report higher rates of nausea and vomiting with GLP-1 class drugs than men do across multiple trials, consistent with baseline sex differences in gastric motility and visceral sensitivity. Tirzepatide is no exception. In SURMOUNT-1, nausea occurred in approximately 32% of participants on 15 mg versus 9% on placebo. Women represent the majority of that 15 mg group, and practical mitigation strategies, including eating smaller meals, avoiding high-fat foods during escalation, and injecting at night so peak drug levels occur during sleep, reduce GI burden.

Injection site reactions occurred in approximately 5% of SURMOUNT-1 participants. Rotating sites among the abdomen, thigh, and upper arm helps. Abdominal injection may produce slightly faster absorption due to proximity to visceral fat, but clinical differences in efficacy by injection site have not been established in tirzepatide-specific data.

What the Pipeline Means Practically: A 2025 to 2028 Outlook

By 2026, you may have access to an oral tirzepatide option if Phase 2 dose-finding resolves the bioavailability challenges. The HFpEF indication for Zepbound is likely to receive FDA action in 2025 or early 2026 based on the SUMMIT filing timeline. Retatrutide may enter Phase 3 in 2025, with potential approval no earlier than 2028 given typical development timelines.

The muscle-preservation combination approach is still early. Do not expect a combined tirzepatide-bimagrumab product before 2028 at the earliest, and only if Phase 2 data support it. For perimenopausal and postmenopausal women worried about losing muscle mass during weight loss, the interim answer is resistance training during tirzepatide therapy and adequate dietary protein, targeting at least 1.2 g of protein per kilogram of body weight per day, a threshold associated with lean mass preservation during caloric deficit.

The oral formulation's sex-specific pharmacokinetics remain an open question. Women's gastric motility changes across the menstrual cycle and with hormonal contraceptive use. If and when oral tirzepatide reaches market, early real-world data stratified by menstrual and hormonal status will be needed to guide dose timing recommendations. Ask your provider to flag updated guidance as it becomes available.